跳至主要内容
临床试验/CTRI/2020/03/024322
CTRI/2020/03/024322已完成未知

Evaluation of the Cumulative Irritation and Potential for Sensitization of Test Products in Healthy Adult Human Subjects by Repeat Insult Patch Testing

The Himalaya Drug Company0 个研究点目标入组 240 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Age 18 to 65 years both inclusive at the time of consent
  • 2 Sex Males and non-pregnant/non-lactating females preferably equal numbers of males and females
  • 3 Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application
  • 4 Subjects who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results
  • 5 Subjects in good general health as determined by the Investigator on the basis of medical history
  • 6 Subjects willing and able to follow the study directions, to participate in the study returning for all specified visits
  • 7 Subjects must be able to understand and provide written informed consent to participate in the study
  • 8 Subjects willing to take bath using the same soap or cleansers during the study period.
  • 9 Subjects willing to refrain from vigorous physical exercise during the study period.

排除标准

  • 1)Subjects having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
  • 2)Medication which may affect skin response and/or past medical history.
  • 3)Subjects having history of diabetes.
  • 4)Subjects have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
  • 5)Subjects suffering from any active clinically significant skin diseases which may contraindicate.
  • 6)Subjects having history of any skin diseases including eczema, atopic dermatitis or active cancer.
  • 7)Participation in any patch test for irritation or sensitization within the last four weeks.
  • 8)Subjects having history of asthma or COPD (Chronic obstructive pulmonary disease).
  • 9)Subjects with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
  • 10)Individual who has a medical condition or is taking or has taken a medication which, in the Investigatorâ??s judgment, makes the subject ineligible or places the subject at undue risk.
  • 11)Subject with known allergy or sensitization to medical adhesives, bandages.
  • 12)Subjects has participation in a clinical drug study or skin irritation/sensitization study during the 30 days preceding the initial patch application in this study.
  • 13)Subject reports a history of skin sensitivity to shampoos and detergents or a known hypersensitivity and/or sensitization to medical adhesives.
  • 14)Subjects reports use of systemic or topical antihistamines (at any site) or uses of topical drugs at patch site(s) within 72 hours prior to patch application.
  • 15)Participation in other patch study simultaneously.
  • 16)Use of any:
  • i.Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
  • ii.Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application.
  • iii.Systemic or topical corticosteroids at patch site within four (4) weeks of Test Product application (steroidal nose drops and/or eye drops are permitted).
  • iv.Topical drugs used at application site.

研究者

相似试验